Business Description

Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. CDX-101, our astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, our zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. Our pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. We also have a commercial business unit that markets ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health. We sell ZanthoSyn® primarily through wholesale and e-commerce channels.

Company Info

Address:
2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822

Telephone:
(808) 457-1400

Fax:
(808) 237-5901

Email:
investors@cardaxpharma.com

Industry Classifications

Sector:
Healthcare

Industry:
Drug Manufacturers

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical Preparations (2834)